Clinical Trials Logo

Pneumococcal Disease clinical trials

View clinical trials related to Pneumococcal Disease.

Filter by:

NCT ID: NCT04642079 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Start date: December 4, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age

NCT ID: NCT04633226 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)

PNEU-PED-KOR
Start date: February 10, 2021
Phase: Phase 3
Study type: Interventional

The primary purpose of this phase 3, single-arm, open-label study is to evaluate the safety and immunogenicity of a 4-dose regimen of V114 administered to healthy infants in South Korea.

NCT ID: NCT04546425 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Start date: September 9, 2020
Phase: Phase 3
Study type: Interventional

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

NCT ID: NCT04530838 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

Start date: September 16, 2020
Phase: Phase 3
Study type: Interventional

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

NCT ID: NCT04526574 Completed - Clinical trials for Pneumococcal Disease

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Start date: September 1, 2020
Phase: Phase 3
Study type: Interventional

Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately

NCT ID: NCT04525599 Completed - Healthy Volunteers Clinical Trials

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Start date: September 22, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of three dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in toddlers who have previously been administered the routine three-dose series of PCV13. This study will also evaluate the immunogenicity (production of an immune response) of three different dose levels of ASP3772 in comparison to the active comparator PCV13 in toddlers who have previously been administered the routine three-dose series of PCV13.

NCT ID: NCT04382326 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Start date: May 20, 2020
Phase: Phase 3
Study type: Interventional

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

NCT ID: NCT04379713 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Start date: May 21, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.

NCT ID: NCT03835975 Completed - Clinical trials for Pneumococcal Disease

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Start date: February 12, 2019
Phase: Phase 3
Study type: Interventional

This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination

NCT ID: NCT03828617 Completed - Clinical trials for Pneumococcal Disease

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Start date: February 14, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind study with a 4-arm parallel design. Adults 18 through 49 years of age with no history of pneumococcal vaccination will be randomized in a 2:2:2:1 ratio to receive a single dose of: 20vPnC Lot 1; 20vPnC Lot 2; 20vPnC Lot 3; or 13vPnC.